European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
Portfolio Pulse from
The European Commission has approved CSL's ANDEMBRY® (garadacimab) for preventing recurrent attacks of hereditary angioedema (HAE). This marks the third regulatory approval for ANDEMBRY, following approvals in Australia and the UK.
February 13, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CSL's ANDEMBRY® has been approved by the European Commission for preventing hereditary angioedema attacks, reinforcing CSL's position in innovative HAE treatments.
The approval of ANDEMBRY® by the European Commission is a significant milestone for CSL, as it expands the market for this innovative treatment in Europe. This approval follows similar endorsements in Australia and the UK, indicating strong regulatory support and potential for increased sales and market penetration. The product's unique once-monthly administration and patient-friendly delivery system further enhance its appeal, likely boosting CSL's revenue and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90